BSc (Hons) (First Class, Brisbane, Australia, 1990), PhD (Aberdeen, 1997)
Manager, Centre for Genome Enabled Biology & Medicine
- About
-
- Email Address
- e.collie-duguid@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437958
- Office Address
School of Medicine, Medical Sciences and Nutrition. Room 4.015. Polwarth Bulding. Foresterhill. Aberdeen. AB25 2ZD
and
Centre for Genome Enabled Biology and Medicine. Room G17. 23 St Machar Drive. Old Aberdeen. Aberdeen. AB24 3RY.
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Elaina Collie-Duguid was awarded a first class BSc (Hons) degree in molecular biology from the University of Queensland, Brisbane, Australia in 1990. Her time as a research assistant at the Centre for Molecular Biology and Biotechnology (currently The Institute of Molecular Bioscience), University of Queensland, was followed by a period of international travel, culminating in a move to Aberdeen in 1993 to begin a PhD in molecular and cellular biology at the Rowett Research Institute. In 1996, Dr Collie-Duguid took up post as a post-doctoral scientist in the Department of Medicine and Therapeutics at the University of Aberdeen and she now heads a Cancer Medicine research group with a particular focus on breast cancer within the Cancer Biomedicine programme.
Dr Collie-Duguid manages the Centre for Genome Enabled Biology and Medicine (CGEBM) at the University of Aberdeen. CGEBM provides strategic direction and coordinated management of the University of Aberdeen’s genomics facilities and facilitates genomics enabled interdisciplinary research by provision of specialised expertise, infrastructure, training, a focal point for collaboration and information exchange and genomics services to the research community. CGEBM provides specialist services in next generation sequencing (NGS), microarrays, bioinformatics and biostatistics. CGEBM helps to drive genome focused research forward by developing and exploiting modern genomic technologies to accelerate discovery of novel approaches to improve human health, the environment and agriculture within the diverse programmes of applied translational, clinical, biomedical and biological research at the University of Aberdeen.
External Memberships
Scientific Member of the Experimental and Translational Medicine Research Committee of the Chief Scientist Office, 2009-2014
Scientific Member of the Biomedical and Therapeutics Research Committee of the Chief Scientist Office, 2005-2009.
- Research
-
Research Overview
Dr Collie-Duguid's research interest is to understand the molecular and cellular mechanisms controlling tumorigenesis, survival of cancer patients and chemoresistance in solid tumours, with a particular focus on breast cancers. Biomarker discovery for prediction of clinical outcomes, including response to therapy; and novel drug target identification for drug development are key elements of her translational research programme. Dr Collie-Duguid has an interest in using genomic tools to understand human disease and important biological processes.
- Teaching
-
Teaching Responsibilities
Dr Collie-Duguid teaches on level 5 courses MB5021 Bioinformatics, MT5003 Drug Metabolism and Toxicology, and MT5515 Research Methods, level 4 PA4302 Molecular Toxicology, level 3 PA3802 Mechanisms of Disease and Principles of Chemotherapy and Intercalated BSc MB ChB teaching in Genetic variation and Bioinformatics, and provides research project supervision to level 5 MSc students in the field of genomics.
- Publications
-
Page 4 of 7 Results 31 to 40 of 64
Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer
Journal of Clinical Oncology, vol. 24, no. 11, pp. 1729-1744Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1200/JCO.2005.03.3399
The Rectal Adenocarcinoma Transcriptome Reveals a Novel Prognostic Biomarker and Candidate Novel Targets for Neoadjuvant Therapy (Aberdeen Microarray in Rectal Cancer Study-1; AMRECS-1)
Colorectal Disease, vol. 8, no. S2Contributions to Journals: ArticlesGene expression profiling of clinical response in rectal adenocarcinomas reveals novel predictive biomarkers and therapeutic targets.
Contributions to Conferences: AbstractsGlobal gene expression profiling of clinical response to radiotherapy and chemoradiotherapy in rectal adenocarcinoma reveals distinct and common molecular mechanisms of action.
Contributions to Conferences: AbstractsIdentification of the lysosomal programmed cell death (PCD) pathway as a critical determinant of clinical response in Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer, vol. 49, no. S141-142Contributions to Journals: ArticlesPutative Novel Mechanisms Of Tomudex Resistance And Insight Into TS-Independent 5-Flurouracil Resistance Networks.
Contributions to Conferences: AbstractsRectal adenocarcinoma transcriptome profiles reveal distinct molecular effects of radiotherapy and chemoradiotherapy (Aberdeen Microarray in Rectal Cancer Study-1; AMRECS-1).
Contributions to Conferences: AbstractsRole of CD200 in tolerance induction: gene expression profiling of lymphoid tissues in response to intranasal antigen.
Immunology, vol. 116, no. 13Contributions to Journals: ArticlesMechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells
Cancer Research, vol. 64, pp. 8167-8176Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1158/0008-5472.CAN-04-0970
Global profiling of molecular mechanisms of 5-fluorouracil, resistance in human cancer cells.
British Journal of Cancer, vol. 91, no. S1Contributions to Journals: Articles